Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

281
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
281
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

724
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
724
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

653
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
653
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to the letter by Tang and Liu Regarding our article "Independent and Dose-Dependent Contributions of Clonal Hematopoiesis and Mosaic Loss of Y to Incident Heart Failure".

European journal of heart failure·2026
Same author

Comparing machine learning methods predicting transcriptome from epigenome with applications to association studies.

Genome biology·2026
Same author

USP22 is a novel vulnerability regulating MEIS1 protein abundance and gene transcription in KMT2Ar acute leukemia.

Blood·2026
Same author

EpiATLAS - a reference for human epigenomic research.

bioRxiv : the preprint server for biology·2026
Same author

Immunomodulatory endothelial cells contribute to T cell recruitment and activation via antigen presentation on MHC II.

Cardiovascular research·2026
Same author

Interpretable multi-omics integration across mixed-order tensors with MANTRA.

Molecular systems biology·2026

Related Experiment Video

Updated: Jan 6, 2026

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.6K

Decoding heart failure subtypes with neural networks via differential explanation analysis.

Mariano Ruz Jurado1,2,3, David Rodriguez Morales1,2,3, Elijah Genetzakis1,4

  • 1Institute of Cardiovascular Regeneration, Theodor-Stern-Kai 7, Goethe University Frankfurt, Frankfurt am Main 60590, Hessen, Germany.

Briefings in Bioinformatics
|November 12, 2025
PubMed
Summary

This study introduces a new method, differentially explained genes (DXGs), to analyze complex single-cell data for heart failure (HF) research. DXGs improve the identification of specific molecular pathways in different HF types.

Keywords:
deep neural networksdifferential gene expressionexplainable artificial intelligenceheart failure subtypes

Related Experiment Videos

Last Updated: Jan 6, 2026

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.6K

Area of Science:

  • Genomics
  • Computational Biology
  • Cardiovascular Research

Background:

  • Single-cell transcriptomics is crucial for understanding heart failure (HF) mechanisms.
  • Analyzing complex single-cell data to find differential gene signatures between HF types is challenging.
  • Machine learning, especially deep neural networks (NNs), aids in analyzing transcriptional patterns but often lacks interpretability.

Purpose of the Study:

  • To develop a novel method for identifying differentially regulated genes in heart failure subtypes.
  • To enhance the interpretability of machine learning models in single-cell transcriptomics.
  • To uncover HF subtype-specific molecular pathways using explainable AI.

Main Methods:

  • Developed a novel method to identify differentially explained genes (DXGs).
  • Utilized importance scores derived from custom-built deep neural networks (NNs).
  • Applied explainable AI (XAI) techniques to interpret NN decisions.

Main Results:

  • DXGs successfully identified HF subtypes-specific pathways.
  • The method demonstrated superiority in pinpointing differentially regulated genes compared to existing tools.
  • New insights into the molecular mechanisms of different heart failure types were revealed.

Conclusions:

  • DXGs offer a robust approach for analyzing complex single-cell transcriptomic data in heart failure research.
  • This method provides a foundation for future research and therapeutic exploration in HF.
  • Enhanced interpretability of machine learning models can accelerate discoveries in cardiovascular disease.